CNS Pharmaceuticals, Inc. (CNSP)
Nasdaq · Healthcare · Biotechnology
$5.30−0.47%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $7.7M
- 52-week range
- $1.90 – $10.59
- 52-week change
- −46.75%
- EPS (trailing)
- −$17.90
Fiscal year to Dec 2025
- Net income
- −$16K
- Diluted EPS
- −$35.75
- Free cash flow
- −$13.8M
From the company’s annual report on SEC EDGAR.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors. The company was incorporated in 2017 and is headquartered in Houston, Texas.
Headquarters: Houston, United States · 8 employees · cnspharma.com